Loading
This page follows insider dealings at אינטרקיור as filed with TASE (ISA). Between 17 October 2025 and 17 October 2026, 4 insiders published 8 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Across the 530 companies tracked on its exchange, the median is 14 filings; at 8 filings, this issuer sits below that mark.
Over the last twelve months, not one insider purchase of אינטרקיור stock was filed.
Every figure here comes from the filings published by TASE (ISA) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
8 of 8 declarations
Intercure is a company listed on the XTAE, specializing in the medical cannabis sector. It focuses on the production and distribution of cannabis-based products in Israel.